| Clinical data | |
|---|---|
| Other names | BTRX-246040 |
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H23ClF2N4O2S |
| Molar mass | 480.96 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BTRX-246040, also known asLY-2940094, is apotent andselectivenociceptin receptorantagonist which is under development by BlackThorn Therapeutics andEli Lilly for the treatment ofmajor depressive disorder (MDD).[1][2][3] It has demonstrated proof-of-concept clinical efficacy for depression.[4] As of 2017, it is inphase IIclinical trials for the treatment of MDD.[1][2][3] It was also under investigation for the treatment ofalcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued.[1]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |